# US 2022/0096451 A1 · Polyvalent derivatives of emoxypine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0096451 A1
- Document ID: US20220096451A1
- Status: Published application
- Kind: A1
- Application number: 17/427,395
- Filed: 2020-02-07
- Published: 2022-03-31
- Earliest claimed: 2019-02-07
- Assignees: ALSaTECH, Inc.
- Applicants: ALSaTECH, Inc.
- Inventors: Claude NICOLAU; Jean-Marie LEHN; Renald THINARD; Youssef ATOINI
- Web page: https://patentgrep.com/patent/US20220096451A1

## CPC

- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 213/65: attached in position 3 or 5
- C07D 213/81: Amides; Imides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Use of polyvalent emoxypine derivatives or related compounds in the treatment or prevention of, inter alia, Parkinson's Disease are described.

## Claims

### Claim 1

A method for treating or preventing a synucleinopathy, comprising administering an effective amount of a polyvalent derivative of emoxypine.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polyvalent derivative of emoxypine is a compound of Formula I:
wherein:
X is —NH—C(═O)— or —CH(═N)—;
each R5, R6, or R7 is independently halo, nitro, OH, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
each t is independently 0, 1, 2, 3, 4, or 5;
each k is independently 0, 1, 2, 3, 4, 5, or 6.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the polyvalent derivative of emoxypine has the structure of:

### Claim 4 (depends on 1)

The method of claim 1, wherein the polyvalent derivative of emoxypine is a compound of Formula II:
wherein:
X is —NH—C(═O)— or —CH(═N)—;
each R1, R2, R3, or R4 is independently halo, nitro, OH, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15;
each t is independently 0, 1, 2, 3, 4, or 5;
each k is independently 0, 1, 2, 3, 4, 5, or 6.

### Claim 5 (depends on 4)

The method of claim 4, wherein the polyvalent derivative of emoxypine has the structure of:

### Claim 6 (depends on 4)

The method of claim 4, wherein the polyvalent derivative of emoxypine has the structure of:

### Claim 7

The method of any of the preceding claims, wherein the synucleinopathy is a condition characterized by Lewy bodies.

### Claim 8

The method of any of the preceding claims, wherein the synucleinopathy is selected from Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

### Claim 9 (depends on 8)

The method of claim 8, wherein the Parkinson's disease is selected from Idiopathic Parkinson's disease, Vascular parkinsonism, drug-induced parkinsonism, dementia with Lewy bodies, Inherited Parkinson's, Juvenile Parkinson's disease.

### Claim 10

The method of any of the preceding claims, wherein the disaggregation of α-synuclein comprises about a 20%, or about a 30%, or about a 40%, or about a 50%, or about a 60%, or about a 70%, or about a 80%, or about a 90%, or about a 95%, or about a 100% reduction in α-synuclein aggregation relative to an untreated subject.

### Claim 11

The method of any of the preceding claims, wherein the method does not substantially dissolve aggregates of beta-amyloid.

### Claim 12

Use of a compound of Formula I in the treatment of a synucleinopathy,
wherein:
X is —NH—C(═O)— or —CH(═N)—;
each R5, R6, or R7 is independently halo, nitro, OH, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
each t is independently 0, 1, 2, 3, 4, or 5;
each k is independently 0, 1, 2, 3, 4, 5, or 6;
wherein the use comprises disaggregation of α-synuclein.

### Claim 13 (depends on 12)

The use of claim 12, wherein the compound of Formula I has the structure of:

### Claim 14

Use of a compound of Formula II in the treatment of a synucleinopathy,
wherein:
X is —NH—C(═O)— or —CH(═N)—;
each R1, R2, R3, or R4 is independently halo, nitro, OH, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15;
each t is independently 0, 1, 2, 3, 4, or 5;
each k is independently 0, 1, 2, 3, 4, 5, or 6;
wherein the use comprises disaggregation of α-synuclein.

### Claim 15 (depends on 14)

The use of claim 14, wherein the compound of Formula II has the structure of:

### Claim 16 (depends on 14)

The use of claim 14, wherein the compound of Formula II has the structure of:

### Claim 17

A method for the treatment of Parkinson's disease, comprising administering an effective amount of a polyvalent derivative of emoxypine of Formula I:
wherein:
X is —NH—C(═O)— or —CH(═N)—;
each R5, R6, or R7 is independently halo, nitro, OH, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
each t is independently 0, 1, 2, 3, 4, or 5;
each k is independently 0, 1, 2, 3, 4, 5, or 6.

### Claim 18 (depends on 17)

The method of claim 17, wherein the polyvalent derivative of emoxypine of Formula I has the structure of:
